कृपया अन्य खोज का प्रयास करें
चिन्ह | एक्सचेंज | करेंसी | ||
---|---|---|---|---|
GRLS | अंतर के लिए अनुबंध (सीएफडी) | EUR | रियल टाइम | |
GRLS | मेड्रिड | EUR | देरी | |
GRLSbn | मेड्रिड | EUR | देरी | |
GRFe | BATS Europe | EUR | देरी | |
GRFPe | BATS Europe | EUR | देरी | |
GIKLY | OTC Markets | USD | देरी | |
GRFS | NASDAQ | USD | रियल टाइम | |
0RDU | लंदन | EUR | रियल टाइम | |
0RDV | लंदन | EUR | रियल टाइम | |
GRFPN | मेक्सिको | MXN | देरी | |
GRLS | विएना | EUR | रियल टाइम |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Darcy Antonellis | 61 | 2023 | Non-Executive Director |
Juan Ignacio Twose Roura | 78 | 1973 | Member of the Advisory Committee |
Tomas Daga Gelabert | 68 | 2000 | Independent External Director |
Raimon Grifols Roura | 60 | 2001 | Vice-Chairman |
Thomas H. Glanzmann | 66 | 2006 | Executive Chairman |
Susana Gonzalez Rodriguez | 47 | 2022 | Independent Director |
Inigo Sánchez-Asiaín Mardones | 60 | 2015 | Independent Director |
Carina Szpilka Lázaro | 56 | 2015 | Lead Independent Director |
Nacho Abia | 56 | 2024 | CEO & Director |
Enriqueta Felip Font | 59 | 2019 | Independent Director |
James Costos | 61 | 2020 | Independent Director |
Montserrat Muñoz Abellana | 55 | 2022 | Independent Director |
Víctor Grifols Deu | 47 | 2016 | Executive Director |
Albert Grifols Coma-Cros | 46 | 2023 | Proprietary Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है